Supernus Pharmaceuticals
Supernus Pharmaceuticals is the current U.S. commercial company behind Myobloc, the principal botulinum toxin type B product in the Botulinum Index graph. Supernus entered the Myobloc relationship through its 2020 agreement to acquire the CNS portfolio of US WorldMeds.
The company connection gives Myobloc a navigable current owner and commercialization node. It does not erase the product’s earlier Solstice Neurosciences and US WorldMeds history, and it should not be interpreted as evidence that type B units are comparable with type A products.
Quick Answers
Section titled “Quick Answers”| Common question | Short answer |
|---|---|
| Who owns or commercializes Myobloc now? | Supernus is the current U.S. company context for Myobloc after acquiring the US WorldMeds CNS portfolio in 2020. |
| What happened to US WorldMeds and Myobloc? | US WorldMeds previously commercialized Myobloc; Supernus agreed to acquire that CNS portfolio, including Myobloc, on April 28, 2020. |
| Is Myobloc the same as Neurobloc? | Myobloc is the U.S. brand name for rimabotulinumtoxinB. Neurobloc was the related European brand name, but EMA materials describe the European authorization as withdrawn. |
| Is Myobloc comparable with Botox or other type A products? | Myobloc is a type B product with its own label, unit system, indications, and safety language. It should not be read as a direct unit or dose peer to type A products. |
Reference Card
Section titled “Reference Card”| Field | Reference point |
|---|---|
| Company | Supernus Pharmaceuticals, Inc. |
| Base | United States |
| Website | supernus.com 🔗 |
| Public status | Nasdaq-listed; ticker SUPN 🔗 |
| Core toxin relationship | Current U.S. commercial portfolio company for Myobloc after the US WorldMeds CNS portfolio acquisition |
| Main brand node | Myobloc / Neurobloc |
| Product identity | RimabotulinumtoxinB, botulinum toxin type B |
| Manufacturing boundary | Supernus reports reliance on third-party contract manufacturers for commercial products; its 2025 annual report also describes a Myobloc contract-manufacturing agreement with Merz |
Related People
Section titled “Related People”| Person | Why the relationship matters |
|---|---|
| Jack A. Khattar | Founder, President, and Chief Executive Officer of Supernus, useful for anchoring Myobloc’s current company context after the US WorldMeds CNS portfolio acquisition. |
| Jonathan Rubin, MD, MBA | Chief Medical Officer and R&D leader, useful for separating Myobloc’s medical and CNS portfolio context from commercial ownership. |
| Todd Horich, Ph.D., MBA | Chief Commercial Officer, useful for connecting Myobloc to Supernus’s commercial organization and CNS portfolio commercialization. |
Ownership and Commercial History
Section titled “Ownership and Commercial History”Myobloc’s earlier company history includes Solstice Neurosciences and US WorldMeds. On April 28, 2020, Supernus announced a definitive agreement to acquire US WorldMeds’ CNS portfolio, including Myobloc, APOKYN, XADAGO, and a late-stage apomorphine infusion product candidate. That transaction moved Myobloc into Supernus’s neurology-focused commercial business.
The acquisition is the key relationship event for the current graph. Supernus is the current commercial company node; US WorldMeds and Solstice remain useful historical names when interpreting older regulatory, corporate, or product materials.
Product Role
Section titled “Product Role”Myobloc is rimabotulinumtoxinB and has a focused U.S. therapeutic role. The U.S. label identifies cervical dystonia and chronic sialorrhea in adults as its indications, and the product is supplied as a ready-to-use injection solution rather than a powder requiring reconstitution. Neurobloc was the related European brand name, though European Medicines Agency materials describe that authorization as withdrawn.
Myobloc is not an aesthetic type A peer. Its serotype, intracellular target, potency units, label, and tolerability context require product-specific interpretation. The label’s unit warning is especially important because type B unit numbers should not be read on the same scale as Botox, Dysport, Xeomin, Jeuveau, Daxxify, Letybo, or another type A product.
Manufacturing and Market Limits
Section titled “Manufacturing and Market Limits”Supernus states that it does not currently own or operate facilities for commercial production of its commercial products and relies on contract manufacturing organizations. Its 2025 annual report also describes a contract-manufacturing agreement with Merz that includes Myobloc manufacturing-facility terms.
That source trail makes the company role more precise: Supernus is the current U.S. commercial portfolio company for Myobloc, while physical manufacturing and packaging should be described through product-specific manufacturing sources rather than inferred from ownership alone.